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Abstract
Objective This population-based survey was conducted to
provide a formal description of upper gastrointestinal
bleeding (UGIB) in children on a nationwide basis and
assess the contribution of risk factors, principally nonste-
roidal anti-inflammatory drugs (NSAID).
Methods A case-crossover study of UGIB patients aged
between 2 months and 16 years was conducted in France.
Medical data were collected by physicians, and personal
risk factors and exposure to drugs during the month
preceding the onset of the bleeding was ascertained by a
standardised telephone interview with parents. The odds
ratios for UGIB and NSAID was assessed by comparing
exposure during the 7 days preceding the date of hospital-
isation and the 21st to the 28th days before that date.
Results A total of 177 children with UGIB were included
over 2 years. Eighty-three children had taken at least one
NSAID before the index date, among which 58 were
ibuprofen, 26 aspirin and nine others. The adjusted odds ratio
(OR) of exposure was 8.2 [95% confidence interval (CI) 2.6–
26.0] for NSAIDs altogether, and this was 10.0 (95% CI 2.0–
51.0) for ibuprofen and 7.3 (95% CI 0.9–59.4) for aspirin.
There was no increased risk associated with NSAIDS for
oesophageal lesion [OR=1.0 [(5% CI:0.2–7.2)].
Conclusion The study confirms that UGIB is rare but that
some cases may be avoided, as one third of the cases was
attributable to exposure to NSAID at doses used for
analgesic or antipyretic purposes, which may be attained
with alternative therapy. The findings from this study call
for more caution in prescribing NSAIDS to children.
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Introduction
Upper gastrointestinal bleeding (UGIB) is a rare but severe
occurrence in children that often requires emergency
treatment. It is generally agreed that the disease presents
itself with haematemesis or maelena that it is favoured by a
medical history of ulcer, coagulation disorders, portal
hypertension and Mallory-Weiss syndrome and that aspirin
and some other nonsteroidal anti-inflammatory drugs
(NSAIDs) play a causative role [1–4]. Data pertaining to
children are, however, limited [5], and the evidence is based
mainly on case reports, series and relatively small cohorts
[6–8]. The actual distribution of anatomical locations and
lesion presentation and the part of the disease attributable to
risk factors and drugs are poorly understood in children.
The role of ibuprofen has been dismissed after a large
randomised double-blind trial of febrile children treated by
paracetamol or ibuprofen concluded there was no statistical
difference in disease risk between the drugs [9]. However,
the four cases of UGIB observed during the study were in
the ibuprofen arm [9]. In clinical practice, the observation
of patients exposed to this drug is relatively frequent, but
the use of the drug is also extremely frequent. Thus, it is
still questionable as to whether ibuprofen is or is not a risk
factor for this disease, and if so, at what dosage. To our
knowledge, no population-based study of drug risk factors
and UGIB in children has been reported. We conducted this
study to provide a formal description of the location and
clinical presentation of UGIB in children and describe the
relative contribution of several risk factors, including drugs.
The study was powered with the primary objective of
assessing the potential contribution of NSAIDs.
Methods
Cases
We conducted a national study in which paediatric gastro-
enterologists from all 32 university hospitals in France were
identified and contacted. Twenty agreed to participate. Two
large regional hospitals were subsequently added. Potential
participants were informed of the study objectives, and
when they agreed to participate, they were visited for study
implementation. Patients to be recruited were children aged
between 2 months and 16 years of both genders with UGIB
defined as oesophageal and/or gastric and/or duodenal
bleeding and presenting with haematemesis, maelena or
haemorrhagic shock. Gastroenterologists were requested to
report all cases identified in their centres during the study
period and to describe clinical presentation using clinical
research forms. Among the items of interest were previous
medical history, symptoms and signs at presentation,
diagnostic procedures applied, severity of the bleeding
and treatment to manage UGIB. Physicians were required
to describe endoscopy findings, if performed. A priori risk
factors included portal hypertension, history of UGIB or
gastric or duodenal ulcer, gastrooesophageal reflux and
coagulation disorders. Consent was obtained by the
physicians from the parent of participating children.
Interviews
Parents were given a self-assessment questionnaire by their
child’s physicians to fill out in preparation for the interview.
Parents were questioned by two independent trained
interviewers who contacted them at home by telephone
and confirmed their consent. The interview was conducted
in the 10 days following UGIB. Information on children’s
drug intake in the 4 weeks before hospitalisation for UGIB
was requested, and parents were asked to have at hand the
written prescriptions and drug packaging information. To
minimize recall bias, parents were informed that drug use as
far as 1 month prior to onset of bleeding was just as
important as recent drug use. Parents were asked to report
the drug(s) used by their children, without any list provided
to them a priori. For each drug reported within the 4 weeks
prior to hospitalisation, indication of use, dosage, duration
of use and date of initiation were requested. Dosages were
recorded as prescribed, usually in milligrams (mg)/kilogram
(kg) per day. Those reported in mg/day were converted to
mg/kg per day (three patients). Drugs were first coded as
reported (usually brand or generic name) and then by class
(antibiotics, antacids, NSAIDs, corticoids, others). We
considered NSAIDs used at the time of the study (aspirin,
ibuprofen, ketoprofen, mefenamic acid, fenamate, tiapro-
fenic acid) and the others. Paracetamol was coded individ-
ually. Drug exposure was defined by at least one drug
intake during risk or control periods (described below).
Sample size
The study was powered to detect a hypothetical relative risk
(RR) of NSAID-related UGIB of 3, with 95% confidence
interval (CI) and 80% power, assuming a prevalence of
NSAID use in children of 4%. The odds ratio (OR) of 3
was chosen because it is usually reported in adults treated
with ibuprofen, the most frequently used NSAID in
children [10]. The prevalence of NSAID use of 4% in the
paediatric population was chosen assuming children are
exposed 2 weeks per year to NSAIDs (personal data). A
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target sample size of 187 children with UGIB was
calculated as required for such a goal. Thirty centres were
initially thought to be necessary for the recruitment.
Design
A case-crossover comparison for the presence of transient
risk factors was chosen for this study. In this design, cases
are taken as their own controls [11] and exposures
compared for different individual time windows considered
as at risk or not at risk for developing the disease as a
consequence of exposure. The predefined periods for
comparisons were the 7 days preceding the date of
hospitalisation (period at risk, or week 1) and the 21st to
the 28th days before that date (control period, or week 4).
Statistical analysis
Crude and adjusted case-crossover ORs were calculated for
exposure to any NSAID during the risk or control periods.
Crude ORs were estimated with methods for matched-pair
studies, by N01/N10 (Mantel-Haenszel estimate for
matched-pair analyses) where N01 is the number of cases
exposed during the risk period and not the control period,
and N10 the number of cases not exposed during the risk
period and exposed during the control period [11]. Sets
where exposures occurred in both periods were considered
as concordant pairs. Potential confounders known to
influence the disease (portal hypertension, history of UGIB
or gastric or duodenal ulcer and coagulation disorders) were
defined a priori. Children with and without those risk
factors were compared regarding NSAID use. Multivariate
conditional logistic regression was performed with all a
priori confounders cited above. All NSAIDs and the three
most used classes of drugs other than NSAIDs were
included into the final model. Results are presented as
means, percentages, and ORs with 95% two-sided CI with
beta set at 20%. Statistical analysis and estimation of OR
and their CI were performed using SAS software version
9.1 (SAS Institute, Inc., NC, USA). The fraction of cases
attributable to an exposure was calculated by the following
formula: (OR-1)/OR. Percentages are rounded to the closest
integer in the text and to the closest decimal in the
tables; 95% CI to OR are presented in parentheses in the
text.
Results
Fourteen university hospitals and two regional general
hospitals recruited cases. Among the 185 cases reported in
24 months, the parents of three children were not able to be
contacted by telephone, and five secondarily declined the
interview. The final data set included 177 patients aged
2 months to 16 years.
Clinical features
The proportion of children 2 months to 2 years old
(33%) reported was relatively more important than those
of other age groups. Haematemesis was present in almost
all children, with the exception of a few younger ones,
and maelena was more frequent in the 2 months to
2 years age group (24% vs. 9%). Most patients (80%)
had undergone endoscopic examination, which showed
difference in lesion location according to age: 37% of
children in the youngest age group presented with gastric
lesions and 52% with oesophageal lesions and 65% and
23%, respectively, in older children. Duodenal lesions
were rare in all age groups. Clinical presentation was
similar in girls and boys (data not shown). The treatment
required was antiulcer and antacid drugs in 60% of
children, transfusion in 11%, miscellaneous in 18% and
none in 21% (Tables 1 and 2).
Risk factors
Thirty-three children had at least one medical risk factor of
bleeding, such as previous medical history of portal
hypertension, personal history of ulcer or UGIB, coagula-
tion disorders or rheumatoid purpura. Details of medical
risk factors are presented in Table 1. Among them, 21.2%
had also used an NSAID at some point during the 4
previous weeks, which is significantly different from the
proportion of NSAID use in children without medical risk
factor (p =0.001).
In the 4-week period prior to bleeding, 79.1% of
children had taken at least one drug. Eighty-three
children (46.9%) had taken at least one NSAID at some
point during these 4 weeks, which was ibuprofen in 70%
of cases, aspirin in 31% and another NSAID in 11%
(Table 3). Other NSAIDs used were fenamate, ketoprofen,
flurbiprofen and naproxen. This use had occurred mostly
in the week at risk. The 3- to 7-year-old age group was the
most exposed to NSAIDs. Fever was reported 69 times
(83%) as the reason for NSAID uses, moderate pain 18
times (22%), rheumatic indication once (1%) and reasons
unknown 11 (13%). NSAIDs dosages used were indeed
mainly those corresponding to the recommended doses for
antipyretic and analgesic treatments: 18.4±11 mg/kg per
day for ibuprofen and 24±16 mg/kg per day for aspirin,
31.75±17 mg/kg per day for fenamates, 1.75±0.25 mg/kg
per day for ketoprofen, 2 mg/kg per day for flurbiprofen
and 11.5 mg/kg per day for naproxen. The mean duration
of NSAID use in the 4 weeks prior to bleeding was short
and in accordance with their indication (1.9±1.5 days); it
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varied from 1.6±1.4 days for aspirin to 1.8±1.4 for
ibuprofen. Other drugs most frequently reported were
paracetamol (37%) and antibiotics (29%).
Table 4 shows the crude and adjusted OR (with 95% CI)
for NSAIDs use during the risk and control periods in the
177 children studied, controlling for the most frequently
used drugs. The adjusted OR of exposure to NSAIDs was
8.2 (2.6–26.0) for NSAIDs altogether, and this was 10.0
92.0–51.0) for ibuprofen and 7.3 (0.9–59.4) for aspirin. The
adjusted OR of exposure to NSAIDs related to oesophageal
lesions was 1.0 (0.2–7.2) and related to gastric or duodenal
lesions 7.9 (1.7–37.5).
The OR for NSAID use and UGIB was 14.1 (2.8–71.2)
and 3.4 (0.6–21.3) in the 2 months to 7 years and 8–
16 years age groups, respectively (p for trend<0.001).
Discussion
To our knowledge, this is the first published population-
based survey of UGIB in children that explores drug risk
factors. Almost half (45%) of the university hospitals of
the country participated, plus two very large regional
hospitals. Recruitment per centre was very close to plans
Table 1 Patient gender and clinical features by age
Age groups
2months to <2years
N=58 (32.8%)
> 3years to <7years
N=60 (33.9%)
> 7years to < 16years
N=59 (33.3%)
Total
N=177
Girls 39 (67.3) 36 (60.0) 33 (56.0) 108 (61.0)
Initial sign
Haematemesis 54 (93.1) 58 (96.7) 59 (100) 171 (96.6)
Maelena 14 (24.1) 6 (10.0) 5 (8.5) 25 (14.1)
Haemorrhage shock 2 (3.5) 2 (3.3) 1 (1.7) 5 (2.8)
Transfusion requirements 4 (6.9) 6 (6.7) 10 (17.0) 20 (11.3)
Hospitalisation 42 (72.4) 46 (76.7) 49 (83.0) 136 (77.4)
Previous medical history
Personal history of ulcer or of upper
gastrointestinal bleeding
3 (5.2) 7 (11.7) 10 (17.0) 20 (11.3)
Portal hypertension 4 (6.9) 3 (5.0) 3 (5.0) 10 (5.7)
Other relevant previous medical history
(coagulation disorders, rheumatoid purpura, other)
4 (6.9) 4 (26.7) 7 (11.9) 15 (8.5)
Table 2 Endoscopy findings (numbers are not exclusive)
2months to <2years N=58
(32.8%)
> 3years to <7years N=60
(33.9%)
> 7years to < 16years N=59
(33.3%)
Total N=177
(%)
Endoscopy performed 46 (79.3) 46 (76.7) 49 (83.1) 141 (79.7)
Endoscopy: normal 8 (17.4) 11 (23.9) 5 (10.2) 24 (17.0)
Endoscopy: unknown 2 (4.3) 1 (2.2) 1 (2.0) 4 (2.8)
Oesophageal lesions 24 (52.2) 10 (22.7) 18 (36.7) 52 (36.9)
- Erythematous
oesophagitis
2 5 10 17
- Erosive oesophagitis 5 2 5 12
- Ulcerated oesophagitis 5 4 4 13
- Varices 3 2 2 7
- Other 3 0 5 8
Gastric lesions 17 (37.0) 30 (65.2) 32 (65.3) 79 (56.0)
- Erythematous gastritis 3 10 11 24
- Erosive gastritis 4 3 5 12
- Ulcerations 0 4 6
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(5.5 vs. 6 cases per centre per year), and the study finally
had the power to assess the risk associated with different
risk factors and drugs by age, gender and clinical
presentation. One case out of five occurred in patients
with a medical risk factor or medical history, and 40% or
more of the children had taken an NSAID in the week
prior to hospitalisation, three quarters of which were
ibuprofen. The frequency of children who took aspirin is
not surprising, as in contrast to most European countries,
aspirin is not contraindicated for use in children in
France. In fact, only a caution of use is included in
aspirin summary of product characteristics (SPC) in cases
of viral infections (flu, chicken pox). In approximately
two thirds of cases, no risk factor was found. Boys and
girls had very similar presentations, and the risk seemed
to decline with age. The results show, for the first time,
that in children, as in adults, there is apparently no
excess risk of oesophageal lesion associated with
NSAIDS [10, 12–14]. According to the findings, there
would be an increased risk of gastric lesions with these
drugs, with no apparent difference between ibuprofen and
aspirin, taken at analgesic or antipyretic doses. The study
confirms that UGIB is rare, so that the absolute risk
associated with these drugs may remain small altogether.
Before exploring these findings further, biases that may
have participated to the observations are discussed. First,
parents may better recall drug intake in their offspring in
the week preceding hospitalisation than those that occurred
several weeks earlier. The fact that, as expected, there was
no increased risk associated with NSAIDs use observed in
Table 4 Crude and adjusted odds ratios (OR) and confidence intervals (CI) for the use of NSAIDs and other classes of drugs in the 4 weeks
before bleeding in the 177 children included in the study
Exposure Week 1 before
bleeding (at-risk) N
Percent Week 4 before
bleeding (control) N
Percent Crude OR
(95% CI)
Adjusted ORb
(95% CI)
All NSAIDs 73 41.2% 8 4.5% 17.3 (6.3-47.3) 8.2 (2.6-26.0)
Oesophageal lesions 11 6.2% 5 2.8% 3.0 (0.6-11.0) 1.0 (0.2-7.2)
Gastric or duodenal lesions 38 21.5% 5 2.8% 11.9 (3.7-39.0) 7.9 (1.7- 37.5)
Ibuprofen 50 28.2% 5 2.8% 23.5 (5.7-96.7) 10.0 (2.0-51.0)
Aspirin 23 13.0% 2 1.1% 22.0 (3.0-163) 7.3 (0.9-59.4)
Other NSAIDs 7 4.0% 2 1.1% 3.5 (0.7-16.8) NC
All NSAIDs in the 2 months
to 7 yearsa age group
56 31.6% 4 2.3% 27.0 (6.6-110) 14.1 (2.8-71.2)
All NSAIDs in the 8 to 16 years
age group
17 9.6% 4 2.3% 7.5 (1.7-32.8) 3.4 (0.6-21.3)
a The 2 months to 2 years and 3- to 7-years age groups were aggregated due to small numbers
b OR were adjusted for the use of paracetamol, corticosteroids, antibiotics, antacids and antiulcer; an adjusted model was applied separately for each drug or
group of drugs studied
NC not calculated due to small numbers
Table 3 Drugs used in the 4 weeks before bleeding, by age
Age groups
2m to 2years N=58 (32.8%) 3to 7years N=60 (33.9%) 8to 16years N=59 (33.3%) Total N=177 (%)
Drugs
- Any NSAIDs 17 40 26 83 (46.9)
● Ibuprofen 12 31 15 58 (32.8)
● Aspirin 5 11 10 26 (14.7)
● Other NSAIDsa 1 4 4 9 (5.1)
- Paracetamol 17 28 20 65 (36.7)
- Antibiotics 15 24 12 51 (28.8)
- Antacids and antiulcer 23 7 10 40 (22.6)
- Other drugs 29 27 22 78 (44.1)
a Fenamates 6, ketoprofen 2, flurbiprofen 1 and naproxen 1. One child took two types of nonsteroidal anti-inflammatory drugs (NSAIDs)
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children with oesophageal lesions (OR=1.0) militates
against an important recall bias, as parents would not know
this difference. Also, there was no significant change
observed in the risk estimates when a more recent time
window (week 3) was used as control (data not shown).
Second, physicians may be more likely to diagnose UGIB
in children exposed to NSAIDs: endoscopic examination
was slightly less frequently performed in children exposed
to NSAIDs than in non-NSAIDs users (72% vs. 84%,
respectively), but NSAIDs users were diagnosed with
severe signs as frequently as nonusers (63% vs. 66%,
respectively); the OR for NSAIDs use in children who had
undergone confirmatory endoscopy were similar to those
observed in the sample as a whole: 7.7 (2.1–28.0) vs. 8.2
(2.6–26.0), respectively. Third, the notoriety of the risk of
UGIB side effects of NSAIDs may have inclined centres to
more frequently report cases recently exposed to NSAIDs
than those that were not. Important efforts were made to
minimize this bias by insisting very frequently on the
necessity to report all cases of UGIB observed. The average
number of cases reported by centre and per year (n=5.5)
over the study period was very close to the number planned
before the study started (n=6) ,and there was no significant
variation in the percentage of exposure recorded per centre.
All in all, we believe that the results are not likely to be
explained fully by these biases. The case-crossover design
has the advantage of controlling efficiently for nontransient
individual confounders, such as genetic, biological or
environmental factors, and has been shown to be efficient
in pharmacoepidemiology [15–17].
Within the NSAIDs category, the risk was similar for
ibuprofen, aspirin or all NSAIDs (adjusted OR 10.0, 7.3
and 8.2, respectively). There was not sufficient use of other
NSAIDs to conclude on their risks individually, but one
cannot exclude the possibility that others may be risk
factors also. However, as they represented a small fraction
of drugs used, the risk for all NSAIDs reflect mainly that of
ibuprofen and aspirin. These results are not inconsistent
with the few data published on NSAIDs and UGIB in
children mentioned in the “Introduction”. Indeed, in a
published series of 231 children who underwent endoscopy
for UGIB, 15% took NSAIDs [6]; from an Australian
hospital adverse drug reactions database, four haematem-
esis with NSAIDs were collected over 5 years, three of
which were associated with ibuprofen (used at the higher
end of the usual range of dose) and one with celecoxib at
too high a dose [8]. The only randomised trial is the Lesko
study [9], which reported more cases of UGIB with
ibuprofen than with paracetamol (four vs. zero cases) but
may have lacked power (although its sample size was
large).
The RR estimated here with NSAIDs use seems higher
than that usually observed in adults (eight vs. two to four).
This may be due to chance or to the fact that children may
have a higher sensitivity to NSAIDs side effects. Alterna-
tive explanations may be that primary exposure to the drugs
may be associated with higher risk, which is the case in
adults [18], or to the so-called depletion of susceptible
effect that we previously demonstrated to occur with
NSAIDs and UGIB in adults [19] (people at risk tend to
be withdrawn from the opportunity to exposure and to
subsequently develop disease more and more with time).
The number of cases reported in the younger age groups
was indeed proportionally much higher than in older
children. The fact that younger patients may be more
readily hospitalised in the presence of bleeding is not
supported by the similar severity and percentage of
confirmed lesions between age groups. The study confirms
that the number of UGIB seen in paediatric units of
university or regional hospitals is few (one case every
other month). Not all cases of this disease are referred to
these hospitals, as some may be seen in general hospitals
without paediatric units. Typically, nonuniversity or nonre-
gional general hospitals accrue a lesser number of cases per
year. Using the numbers observed and applying different
hypothesis yields estimates between 1,000 and 2,000 cases
per year in France, which is an incidence in the vicinity of
1–2 per 10,000 children per year in the 2 months to
16 years old age group (12,000,000 in the country).
According to this study, the fraction of cases attributable
to NSAIDs would be 88% of the 41% exposed in the week
before occurrence, which is 36%.
To conclude, this study confirms that UGIB is rare,
occurs more likely in children of younger age and shows
that it is attributable to the use of NSAIDs, including
ibuprofen and aspirin, in approximately one third of cases.
Some of these cases may be avoided by using alternative
drugs such as paracetamol for analgesic or antipyretic
purposes, particularly in patients with medical risk factors
for the disease. The findings from this study call for more
caution in prescribing NSAIDs to children.
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